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Prevalence of hepatitis B genotype C in injection drug
users in the northeastern Indian state of Manipur, neighbor-
ing the “Golden Triangle,” correlates well with overland
drug-trafficking routes, the injection drug use epidemic, and
the spread of HIV. Further spread to other regions of India
through mobile populations is possible.
I
njection drug use is common in countries neighboring
the “Golden Triangle” (Myanmar, Laos, and Thailand),
known for heroin export to other countries. HIV and injec-
tion drug use outbreaks in countries neighboring the
Golden Triangle, including the northeastern Indian state of
Manipur, have been associated with drug-trafficking routes
(1). Manipur shares a 358-km porous border with
Myanmar. According to the National AIDS Control
Organization, India (www.nacoonline.org), HIV infection
rates among injection drug users in Manipur increased
from 2%–3% in 1989 to >50% in 1991 and ≈64% in 2000.
In addition, exposure rates of 100% for hepatitis B virus
(HBV) and 92% for hepatitis C virus (HCV) have been
detected among injection drug users in Manipur, and 95%
of wives of injection drug users had HBV exposure (2).
However, among both the users and their wives, preva-
lence of HBV genotypes and occult HBV infection (3), a
known risk factor for hepatocellular carcinoma (HCC) (4),
remained unknown.
HBV is classified into 8 genotypes, HBV/A through
HBV/H, and is further divided into subgenotypes (5) that
have a distinct geographic distribution and are associated
with different disease outcomes. The geographic distribu-
tion of HBV is known to correlate with the anthropologic
history of migration (5) and to the origin and routes of
spread of HBV infection. In addition, behavioral patterns
are known to change HBV genotype distribution in a
region (6).
Manipur is an important location, where mainland India
(prevalent genotypes HBV/A, HBV/D) geographically
meets China and Southeast Asia (prevalent genotypes
HBV/B, HBV/C). Our study was designed to detect HBV
DNA among injection drug users in Manipur and to ana-
lyze HBV genotypes for correlation with injection drug
use and the HIV epidemic.
The Study
We examined HIV-positive injection drug users from
Manipur who had been identified as anti-HBc–positive
during previous serosurveys conducted by the National
Institute of Cholera and Enteric Diseases (2). Serum sam-
ples (stored at –80ºC) taken from 63 men 18–25 years of
age were available for the study. HBsAg detection was
repeated with a monoclonal antibody–based Hepanostika
hepatitis B surface antigen (HBsAg) kit (bioMérieux,
Marcy l’Etoile, France). Anti-HCV antibody was detected
using the Ortho HCV 3.0 test (Ortho-Clinical Diagnostics,
Raritan, NJ, USA). We completed HBV DNA isolation,
PCR amplification, genotype/subgenotype/subtype identi-
fication, recombination detection, and HBV DNAquantifi-
cation with methods described earlier (7–9). We also
compared nucleotide (online Appendix Table, available at
http://www.cdc.gov/ncidod/EID/vol12no12/06-0425
appT.htm) and deduced amino acid sequences (Table) with
consensus sequence of amino acids of corresponding
genotypes to detect substitutions (GenBank accession nos.
DQ356432–DQ356441).
All those tested were HBsAg negative, and only 10
(15.9%) had detectable HBV DNA. Anti-HCV was detect-
ed in all but 1 sample (no. 4). Serum HBV DNA level was
detectable in 5 of 10 samples (Table); the rest were below
the detection limit of our assay.
HBV/C (all subtype adr except 1 adw2) was the pre-
dominant genotype, with 4 subgenotype C1 (HBV/C1) and
3 subgenotype C2 (HBV/C2) isolates. HBV/A1 adw2 was
found in 1 of the isolates. Two other isolates (nos. 1 and 3,
subtype adw2) indicated a possibility of intergenotypic
recombination (Figure 1), but subgenotype could not be
assigned for them.
BLASTN search (www.incogen.com/public_docu-
ments/vibe/details/NcbiBlastn.html) of sequence from
sample no. 1 showed similarity to HBV/D as well as to
HBV/A sequences from European countries. On the other
hand, sequences from sample no. 3 showed similarity to
HBV/C and HBV/A sequences from Southeast Asian
countries and India. Simplot analysis confirmed recombi-
nation in these 2 isolates (Figure 2). Apart from the geno-
type-specific substitutions, deduced amino acid sequences
did not have any remarkable escape mutant other than
G145R in 2 isolates (Table).
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The data from this study showed occult HBV infection
in 15.9% of the injection drug users tested. The rate of HBV
DNA detection (10%–45%) was considerably different in
studies reported from different cohorts of injection drug
users in different countries, a finding that has been attrib-
uted to coinfection with HCV or low HBV DNAlevels (3).
Apart from HIV, our study group had a high frequency of
HCV infection and low HBV DNA levels. Undetectable
HBsAg, except in 2 cases with G145R substitution, may
also be a result of the above-mentioned factors.
Although the importance of occult HBV infection is not
well understood, a recent study reported occult HBV to be
a significant risk factor for HCC, especially among per-
sons who were anti-HBc–positive (4). Another recent
study among HIV-infected patients documented death due
to liver disease in 22% who were HBV coinfected, 44%
who were HCV/HBV coinfected, and 15% who were HBV
coinfected and had HCC (10). Thus, the clinical relevance
in our study group also needs to be followed.
Although we detected a 100% prevalence of anti-HBc
in our serosurveys (2), only 1 was HBsAg-positive.
Therefore, the distribution of genotypes among those who
were HBsAg positive could not be determined.
Findings of HBV/C1 (prevalent in China) appear to
support the history of human migration from China to
northeastern India. However, we did not detect HBV/B,
also prevalent in China. Further, we did detect HBV/C2,
which has close similarity to strains from Southeast Asian
countries. The presence of HBV/C correlated well with
drug-trafficking routes and the injection drug use epidem-
ic. The geographic proximity of Manipur to the Golden
Triangle, needle sharing among injection drug users, and
drug traders thus contributed to the spread of HBV through
drug-trafficking routes, similar to HIV (1).
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Figure 1. Phylogenetic relationships among the sequences of s
gene from hepatitis B virus strains isolated in this study (shown
with prefix “IDU”) compared with reference sequences from
GenBank (accession nos. are shown). Genotype and subgeno-
types are indicated at each main branch and subbranch, respec-
tively. Percentage of bootstrap replications supporting the clusters
(>75%) are also shown at the nodes.In Manipur, HIV subtypes C and Thai B are prevalent
(11); these are also prevalent in the India-Myanmar and
China-Myanmar border regions. The presence of similar
HIV subtypes among injection drug users in Manipur sup-
ports the presence of similar HBV strains (e.g., HBV/C1,
HBV/C2) and their cotransmission through drug-traffick-
ing routes. In addition, circulation of recombinant HBV is
common among injection drug users because of repeated
exposure (12). The intergenotypic HBV recombinants
found in this study are thus expected. HBV/C has been
associated with advanced liver disease and poses a higher
risk for HCC in Asians (13) than does HBV/B. However,
the clinical relevance of HBV recombinants and their
pathogenesis is not well understood and needs further
investigation.
Poor, unemployed youths in the northeastern states of
India are being recruited for drug trafficking to other
regions (www.ipcs.org). Furthermore, national highways
are associated with the prevalence of injection drug use in
rural Manipur (14). As these highways connect Manipur
with other parts of India, HBV/C may spread from
Manipur to other parts of the country through persons who
travel regularly, such as truck drivers and drug traffickers.
Presence of HBV genotypes A and D among patients
from northern and western India is well documented.
Recent research reported HBV/C with close similarity to
Southeast Asian strains only from eastern India (9,15) and
suggested injection drug users as a possible route of intro-
duction (15). In addition, persons from northeastern India
frequent Kolkata for education, employment, medical
treatment, and other purposes. Studies on these mobile
populations might provide further important information
on the route, population at risk for infection, and changing
epidemiology of these viral infections in other regions.
In conclusion, HBV/C, associated with severe liver dis-
ease in Southeastern Asia, may be emerging in the
Manipur state of India through the trafficking routes of
injection drugs. This genotype could spread to the general
population through different modes. In light of growing
information on the severity of liver disease in HBV-infect-
ed HIV/HCV patients, injection drug users should be the
focus of additional education and healthcare efforts. The
possibility of further spread of HIV/HBV/HCV through
mobile populations to other regions of India warrants
attention and further investigation.
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Figure 2. The location of recombination events in isolates IDU1 (A)
and IDU3 (B), determined by using the bootscanning program of
Simplot. Possible tree topologies (a,b, and c) are shown (C). The
phylogenetically informative sites and the tree topologies support-
ed at each of those sites are indicated over each plot. In the tree
topologies, Q, A, and H indicate query sequences (IDU1 or IDU3),
genotype A, and genotype H (outgroup) consensus sequences,
respectively. S indicates consensus sequence of genotype D and
genotype C for IDU1 and IDU3, respectively. Possible crossover
points are indicated by solid triangles. A sliding window size of 60
bp, step size of 10 bp, Kimura-2 parameter, 1,000 bootstrap repli-
cates, and neighbor-joining method were used for the analysis of
recombination.References
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